This Global website is not intended to represent or suggest that particular products are approved or
authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for
any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable
law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized
in particular countries, please consult the appropriate
CSL Behring offers one of the world's most comprehensive portfolios of safe, high quality, technically advanced immunoglobulin (Ig) products designed
to offer patients the convenience, choice, and ease of administration that they seek.
Immunoglobulin, or Ig, is a component of healthy human blood plasma. Some people are born with low or absent levels of Ig in their blood, or with an immune system that does not function properly. Such a condition makes fighting off common germs and infections extremely difficult – if not impossible. Immunoglobulin
therapy replaces Ig that is present in an insufficient quantity.
The body's immune system can then work more effectively.
World Health Organization
has identified more than 100 immunodeficiencies, ranging from extremely rare (severe combined immunodeficiency affects one individual in 1 million) to the more common selective
immunoglobulin A (IgA) deficiency, which occurs in approximately one in 500 individuals. Some of the products in the CSL Behring portfolio also effect a change in the body's immune system; that is, they work to activate or suppress its function. These are called immunomodulators.
CSL Behring Immunoglobulin Products
The CSL Behring product portfolio includes key immunoglobulin (Ig) products designed to be administered either intravenously (IVIg) or subcutaneously (SCIg).
These various methods of administration provide flexibility and choice for people managing a health condition for which immunoglobulin (Ig) therapy is prescribed.
Highlights of CSL Behring's immunoglobulin portfolio include:
Privigen® is the first and only intravenous 10%, ready-to-use liquid immunoglobulin (Ig) therapy
made with L-proline.
provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body. Privigen is always ready to use; it requires
no refrigeration throughout its 36-month shelf life.
Hizentra®, the first and only ready-to-use 20% solution for subcutaneous infusion (SCIg), is a weekly or bi-weekly therapy that can be safely self-administered.
Hizentra® provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body. Made with L-proline, Hizentra is ready to use; it requires no refrigeration throughout its 30-month shelf-life, offering patients and physicians convenience, portability and flexible dosing.
- Carimune®, also brand-named Sandoglobulin® in some markets, has a long track record of safety and
reliability and is an Ig option for patients and healthcare professionals who prefer a lyophilized preparation.
CSL Behring's Immunoglobulin (Ig) Therapy product portfolio also includes hyperimmune immunoglobulins – various immunoglobulin preparations especially high
in antibodies against certain diseases. At CSL Behring, these products include treatments for tetanus, varicella, rabies, hepatitis A and B, as well as an anti-D that
fights idiopathic thrombocytopenic purpura (ITP) and that prevents hemolytic disease of the newborn (HDN). HDN is caused by blood group mismatch between mother and baby. Our anti-D is used in Rh-negative women during pregnancy to prevent Rhesus immunization of the mother and the resulting risk of hemolytic disease of the newborn.
Hyperimmune Igs are also administered following solid organ transplant surgery to prevent cytomegalovirus (CMV), a potentially life-threatening infection.
Product availability varies from country to country, depending on registration status. Please contact your local CSL Behring representative for more information.